|Type||Public limited company|
|Headquarters||London, United Kingdom|
|Parent||University College London|
UCL Business PLC (UCLB) is the technology-transfer company of University College London (UCL) and is headquartered in London, United Kingdom. It is a wholly owned subsidiary of UCL and is responsible for conducting technology development and commercial transactions for the university. It is based on Tottenham Court Road in the Camden area of Central London.
UCL's first technology-transfer company was founded in 1989 as UCL Ventures. In February 2001 UCL Ventures, together with the technology-transfer companies of the University of Bristol, the University of Southampton and Imperial College London, signed a deal with a £100 million investment fund. UCL Ventures merged with the technology-transfer company of the Royal Free Hospital, Freemedic plc (founded in 1993) to form UCL Biomedica PLC.
UCL Business PLC was created in August 2006 through the merger of UCL BioMedica with UCL’s internal knowledge transfer department, also known as UCL Business. The former UCL Business had been established to provide a link between UCL's academics and industry, and to aid the development of commercially valuable technologies arising from UCL, whilst UCL BioMedica had been established to commercialise opportunities arising from UCL’s biomedical research strengths, as well as to conduct clinical trials. The integration of the two technology transfer activities created a single organisation focused on delivering the complete commercialisation process from patent registration and support for the creation of new businesses, through to licensing and sales of technologies to industry partners.
UCLB provided advice and a grant support to Siavash Mahdavi in helping him to establish the robotics company Complex Matters. In September 2007 UCLB and UCL were sued for unlimited damages by Geoffrey Goldspink in respect of patents for mechano growth factor. UCLB has been providing regulatory support to a team of researchers from UCL that in August 2009 won a £500,000 grant towards the development of a synthetic artery that mimics a natural artery.
UCLB has equity stake in all of its companies, the majority being spin-outs arising from technologies developed across the full range of faculties within UCL, including biomedical, biotechnology, engineering, mathematics, physical sciences and build environment companies. These include Ark Therapeutics Ltd, Arrow Therapeutics Ltd, Biovex Ltd, Canbex, Domainex Ltd, Evexar Medical Ltd, Genex Biosystems, Inpharmatica Ltd, Intercytex, Medic-to-Medic, Pentraxin Therapeutics, PolyMASC Pharmaceuticals PLC, Proaxon, Spirogen Ltd, Stanmore Implants Worldwide Ltd, Advanced Design Technology, AS Built Solutions, Bloomsbury DSP, Endomagnetics, EuroTempest, Ixico, Quantemol, Senceive, Space Syntax, Zinwave.
UCL Consultants is a subsidiary of UCL Business which undertakes consultancy projects for organisations of all sizes, including:
- Central, local and regional government departments
- Research institutes
UCL Consultants provides access to specialist knowledge and research facilities across UCL and direct links to UCL's academic staff. To date UCL Consultants has contracted over 1,000 consultancy projects worth over £35 million, with national and international clients including multinational companies, small and medium sized enterprises, charities and local, regional and central Government departments.
- "About UCL Business". UCL Business PLC. Retrieved 31 October 2010.
- "Contact us". UCL Business PLC. Retrieved 31 October 2010.
- "Calling for entrepreneurs London". Nature. 19 September 2002. Retrieved 31 October 2010.
- "Box 1. Transferring ideas". Nature. 19 September 2002. Retrieved 31 October 2010.
- "£100m deal to fund spin-offs". Times Higher Education. 23 February 2001. Retrieved 31 October 2010.
- "UCLB: Building Commercial Success". UCL Business PLC. p. 7. Retrieved 8 December2010.
- "Siavash Mahdavi, University College London". The Engineer. 15 June 2007. Retrieved 31 October 2010.
- "UCL is sued over $1bn deal". Times Higher Education. 21 September 2007. Retrieved 31 October 2010.
- "Synthetic artery". The Engineer. 11 August 2009. Retrieved 31 October 2010.
- "University Finds Rewards and Risks in Business Start-Ups". The New York Times. 13 February 2011. Retrieved 25 April 2011.
- "UCL spin out sold to Amgen in $1 billion deal". Science Business. 27 January 2011. Retrieved 25 April 2011.
- "Biomedical and Biotechnology Companies". UCL Business PLC. Retrieved 8 December2010.
- "Engineering, Physical Science and Built Environment Companies". UCL Business PLC. Retrieved 8 December2010.
- "About UCL Consultants". UCL Business PLC. Retrieved 8 December2010.